NEW YORK (GenomeWeb) – Nucleix said today that it has received a CE Mark for its Bladder EpiCheck test, which is intended to help urologists better monitor bladder cancer patients.

Bladder EpiCheck is a urine test that utilizes multiplexed real-time PCR to analyze a panel of 15 methylation markers.